Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West(Vyne Therapeutics (United States)), Federico Cappuzzo(Ospedale di Livorno), Venice Archer(AstraZeneca (United Kingdom)), Hans‐Georg Kopp(Robert Bosch Hospital), Henry Jacob Conter(William Osler Health System), Achim Rittmeyer(Unknown), Tania Ochi Lohmann(Roche (Switzerland)), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alona Zer(Rambam Health Care Campus), Davey B. Daniel(Tennessee Oncology), Maen Hussein(Sarah Cannon), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Alan Sandler(Chinese University of Hong Kong), Michael McCleod(Sarah Cannon), Lijia Wang(University of Shanghai for Science and Technology), Ahad A. Sadiq(Fort Wayne Medical Institute), Steven McCune(Northwest Behavioral Medicine), Marcin Kowanetz, Tarek Mekhail(AdventHealth Orlando), Wei Lin(Chinese University of Hong Kong)
Cited by 1,676
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k